陶氏病
细胞生物学
神经炎症
细胞内
热休克蛋白90
细胞外
生物
τ蛋白
药理学
阿尔茨海默病
神经科学
化学
生物化学
神经退行性变
炎症
热休克蛋白
免疫学
疾病
医学
病理
基因
作者
Yongming Tang,Dongju Zhao,Fan Yang,Gaoju Pang,Zuhao Sun,Jin Chang,Yan Dou
标识
DOI:10.1016/j.cej.2021.134352
摘要
Tau pathology is a major hallmark and potential drug therapeutic target of Alzheimer’s disease (AD). Effective clearance of hyperphosphorylated tau protein (p-tau) is very difficult, not only because the intracellular repair defense collapses and degradation fails, but also because the extracellular pathological environment always aggravates its production. Herein, hollow mesoporous prussian blue nanoparticles (HMPB NPs) loaded with a high-affinity Hsp90 inhibitor 17-AAG are constructed as HMPB-AAG nanoagents for the combined rescue of tauopathy-induced AD. In this nanoagent, 17-AAG achieves Hsp90 co-chaperone degradation of p-tau and HMPB NPs exert antioxidation property. In vitro and in vivo studies reveal that HMPB-AAG nanoagents can produce a combinational therapeutic effect on tau-related pathology by reducing p-tau levels, alleviating oxidative stress and neuroinflammation, and inhibiting neuronal apoptosis and synaptic damage. Hippocampal stereotaxic microinjections of HMPB-AAG nanoagents into okadaic acid-induced AD-like rats have shown to significantly reverse tauopathy-induced cognitive impairment. Overall, this work takes advantage of the combination of intracellular and extracellular regulatory strategies targeting tau hyperphosphorylation, providing a promising and efficient therapeutic candidate agent for AD and other tau-related neurodegenerative diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI